Yes, prednisone will likely worsen an active systemic fungal infection and should be avoided or minimized.
Prednisone is contraindicated in systemic fungal infections 1. The FDA drug label explicitly states that prednisone may exacerbate systemic fungal infections and recommends avoiding its use in the presence of such infections unless needed to control drug reactions 1. In patients already on chronic prednisone who develop systemic fungal infections, withdrawal or dosage reduction is strongly recommended 1.
Why Prednisone Worsens Fungal Infections
Corticosteroids fundamentally impair the immune system's ability to fight fungal pathogens through multiple mechanisms:
- Suppress immune defenses: Prednisone reduces resistance to new infections, exacerbates existing infections, increases risk of disseminated disease, and masks signs of infection 1
- Impair fungal clearance: Corticosteroids suppress NF-κB signaling, downregulate TNF-α production, and promote IL-10 secretion, creating a Th2-skewed immune profile that favors fungal growth 2
- Dysregulate neutrophil function: While neutrophil recruitment persists, it becomes ineffective at pathogen elimination and instead contributes to tissue injury 2
- May directly enhance fungal growth: Evidence suggests corticosteroids can promote Aspergillus proliferation beyond just immune suppression 2
Evidence of Worse Outcomes
The data consistently show increased mortality with corticosteroids in invasive fungal disease:
- Invasive aspergillosis: Corticosteroid therapy increases mortality risk (HR: 2.50,95% CI: 1.89-3.31) 3. Doses exceeding 2 mg/kg/day prednisolone equivalents further increase mortality (HR: 2.94,95% CI: 2.13-4.05) 3
- Chronic pulmonary aspergillosis: Corticosteroids worsen outcomes (HR: 2.74,95% CI: 1.48-5.06) 3
- Invasive candidiasis/candidemia: Corticosteroids increase mortality (OR: 2.13,95% CI: 1.85-2.46) 3
- Mucormycosis: Corticosteroids dramatically worsen outcomes (OR: 4.19,95% CI: 1.74-10.05) 3
- Pneumocystis jirovecii pneumonia (non-HIV): Corticosteroids worsen outcomes (OR: 1.29,95% CI: 1.09-1.53) 3
Corticosteroid treatment is a major risk factor for developing fungal superinfections in viral pneumonia patients (p < 0.00001) 4.
Clinical Management Algorithm
For a patient with suspected or confirmed invasive fungal pneumonia:
Stop or minimize prednisone immediately unless absolutely required for another life-threatening condition 1
Initiate appropriate antifungal therapy urgently:
Monitor for infection development if prednisone cannot be discontinued, as infectious complications increase with dosage 1
Consider prophylactic antifungals if prolonged high-dose corticosteroids (>2 weeks) are unavoidable 8
Important Caveats
The only exception where corticosteroids may have a role in fungal disease is in chronic disseminated candidiasis (hepatosplenic candidiasis), where some evidence suggests corticosteroids at 0.5-1 mg/kg/day prednisone given in conjunction with antifungal agents may improve inflammatory symptoms 7. However, this role remains unclear and controversial 7.
For diffuse pulmonary histoplasmosis requiring ventilatory support, prednisone 60 mg daily for 2 weeks may be considered alongside antifungal therapy 9, though this is specific to histoplasmosis and not applicable to other invasive fungal infections.
In your clinical scenario of invasive fungal pneumonia with hypoxemia, prednisone should be discontinued or minimized while aggressive antifungal therapy is initiated. The risk of worsening the fungal infection and increasing mortality far outweighs any potential anti-inflammatory benefit.